For chief executive officers at biopharmaceutical companies, R&D directors in genetic medicine divisions, and investors tracking next-generation therapeutics, a persistent strategic challenge has historically defined drug discovery: approximately 85% of human disease-associated proteins are considered “undruggable” by conventional small molecules or biologics due to lack of active sites or inaccessible cellular locations. Nucleic acid-based drugs directly resolve this limitation by intervening at the genetic level—using antisense oligonucleotides (ASOs), siRNA, mRNA, aptamers, and gene-editing vectors as active ingredients to modulate gene expression or directly replace/modify genetic information with high target specificity and sequence designability. According to the latest industry benchmark, the global market for Nucleic Acid-based Drugs was valued at USD 14,636 million in 2024 and is forecast to reach a readjusted size of USD 21,728 million by 2031, growing at a steady compound annual growth rate (CAGR) of 7.5% during the forecast period 2025-2031. This growth reflects accelerating clinical translation, regulatory acceptance, and commercial-scale manufacturing of mRNA vaccines, siRNA therapies, and ASO drugs, positioning nucleic acid therapeutics as a core disruptive track in the pharmaceutical industry, with average gross profit margins reaching approximately 85%.
*Global Leading Market Research Publisher QYResearch announces the release of its latest report “Nucleic Acid-based Drugs – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Nucleic Acid-based Drugs market, including market size, share, demand, industry development status, and forecasts for the next few years.*
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5181077/nucleic-acid-based-drugs
1. Product Definition: Gene-Level Intervention with High Specificity and Designability
Nucleic acid-based drugs are a new generation of biologics that use nucleic acids—including but not limited to antisense oligonucleotides (ASOs), small interfering RNA (siRNA), messenger RNA (mRNA), aptamers, and gene-editing vectors (CRISPR/Cas9)—as active ingredients to modulate gene expression or directly replace/modify genetic information for therapeutic effect. Unlike conventional small molecules or protein therapeutics, nucleic acid drugs can intervene at the molecular root of disease with high target specificity and sequence designability, enabling access to historically “undruggable” targets (e.g., transcription factors, non-enzymatic proteins, intracellular targets inaccessible to antibodies).
Key technology platforms (segment by type – QYResearch classification):
- Antisense Oligonucleotides (ASO) – Single-stranded synthetic nucleic acids (typically 15-25 nucleotides) that bind to complementary RNA sequences, modulating RNA splicing, increasing degradation of target RNA, or blocking translation. Approved drugs: nusinersen (Spinraza, Biogen/Ionis) for spinal muscular atrophy; eteplirsen (Exondys 51, Sarepta) for Duchenne muscular dystrophy; inotersen (Tegsedi, Ionis) for hereditary transthyretin amyloidosis (hATTR).
- siRNA (small interfering RNA) – Double-stranded RNA molecules (21-23 base pairs) that trigger RNA interference (RNAi), leading to sequence-specific degradation of target mRNA. Approved drugs: patisiran (Onpattro, Alnylam) for hATTR; givosiran (Givlaari, Alnylam) for acute hepatic porphyria; inclisiran (Leqvio, Novartis/Alnylam) for hypercholesterolemia.
- mRNA (messenger RNA) – Single-stranded RNA encoding therapeutic proteins, delivered to cells for transient protein expression. Approved vaccines: COVID-19 mRNA vaccines (Comirnaty – Pfizer/BioNTech, Spikevax – Moderna). Emerging applications: cancer immunotherapy (personalized neoantigen vaccines), protein replacement therapies (rare diseases), and prophylactic vaccines (influenza, RSV, HIV).
- Other – Aptamers (single-stranded oligonucleotides that bind to specific targets with high affinity), gene-editing vectors (CRISPR/Cas9 delivered via viral or non-viral vectors), plasmid DNA vaccines.
Key therapeutic areas (segment by application):
- Neuromuscular Diseases – Spinal muscular atrophy, Duchenne muscular dystrophy, myotonic dystrophy. Key players: Sarepta Therapeutics, Ionis Pharmaceuticals, Biogen, Nippon Shinyaku.
- hATTR (hereditary transthyretin amyloidosis) – Rare, progressive, often fatal disease caused by misfolded transthyretin protein. Key players: Alnylam (Onpattro), Ionis (Tegsedi), Pfizer (Vyndaqel, not nucleic acid but TTR stabilizer).
- COVID-19 – mRNA vaccines from Pfizer/BioNTech, Moderna. Emergency use authorizations transitioned to full approvals in multiple jurisdictions (FDA, EMA, PMDA, NMPA). Ongoing variant-specific updates and bivalent formulations.
- Other – Hypercholesterolemia (inclisiran), acute hepatic porphyria (givosiran), primary hyperoxaluria (lumasiran), complement-mediated diseases (ravulizumab – not nucleic acid, but illustrating rare disease focus), and expanding oncology pipeline (personalized cancer vaccines, siRNA targeting oncogenes).
2. Industry Development Trends: Technology Convergence, Regulatory Acceptance, and Capital Inflows
Based on analysis of corporate annual reports (Alnylam, Ionis, Sarepta, Moderna, BioNTech, Pfizer), regulatory approvals, and industry news from Q4 2025 to Q2 2026, four dominant trends shape the nucleic acid-based drugs sector:
2.1 Technology Convergence: mRNA, LNP, and Modified Nucleotides
In recent years, advances in mRNA platforms, chemically modified nucleotides (to reduce immunogenicity and enhance stability), and delivery systems (particularly lipid nanoparticles, LNPs) have significantly accelerated clinical translation and industrial-scale manufacturing. The success of COVID-19 mRNA vaccines validated the LNP-mRNA platform for prophylactic use, with billions of doses manufactured globally. This platform is now being repurposed for: (1) personalized cancer vaccines – mRNA encoding patient-specific neoantigens, in combination with checkpoint inhibitors (PD-1/PD-L1). Moderna and Merck’s mRNA-4157 (personalized melanoma vaccine) entered Phase III in 2025; (2) rare disease protein replacement – mRNA encoding missing enzymes, delivered via LNP to liver or other target organs; (3) vaccines for infectious diseases – influenza, RSV, CMV, HIV, Zika. The platform learnings are also applicable to siRNA and ASO delivery (LNPs for liver targeting, GalNAc conjugates for hepatocyte-specific delivery), moving the field rapidly from research-driven innovation toward commercialization.
2.2 Regulatory Acceptance and Public Health Prioritization
Regulatory acceptance and public health prioritization have integrated nucleic acid products into national biopharmaceutical strategies, generating policy and procurement support. Key milestones:
- US FDA – Established dedicated review divisions for gene therapies and nucleic acid drugs; breakthrough therapy and fast-track designations for multiple candidates. The FDA’s “Platform Technology” guidance (December 2025) recognizes modular nucleic acid platforms (e.g., LNP-mRNA), potentially streamlining future approvals for platform-derived products with similar manufacturing processes.
- China NMPA – Granted approval for domestic mRNA vaccine (ARCoV, Walvax/Abogen/Chinese PLA Academy of Military Sciences) and multiple siRNA candidates in clinical development. China’s 14th Five-Year Plan for Biopharmaceuticals identifies nucleic acid therapeutics as a strategic priority, with dedicated funding and regulatory fast-track pathways.
- EMA (Europe) – Conditional marketing authorizations and accelerated assessments for nucleic acid products addressing unmet medical needs (e.g., inclisiran for hypercholesterolemia, approved with innovative pricing model linked to LDL-cholesterol reduction).
- Global Access – WHO prequalification for nucleic acid drugs (e.g., COVID-19 mRNA vaccines) has established pathways for low- and middle-income countries.
2.3 Capital Inflows and Ecosystem Maturation
Sustained capital inflows and the commercial success of approved nucleic acid therapies (Spinraza annual sales exceeding USD 1.7 billion; Onpattro peak sales >USD 400 million; COVID-19 mRNA vaccines >USD 50 billion combined 2021-2023) are building an end-to-end ecosystem—from upstream materials (modified nucleotides, LNPs, enzymes) and CMC (chemistry, manufacturing, controls) to downstream distribution (cold chain logistics for mRNA vaccines at -20°C to -80°C). Venture capital investment in nucleic acid platforms reached USD 8-10 billion annually in 2024-2025, funding over 200 startups globally. For companies with robust platforms and regulatory experience, this capital environment creates immediate market expansion opportunities. However, intensifying competition means that without differentiated platforms and reliable manufacturing capability, new entrants will struggle to secure sustainable market positions.
2.4 Delivery Efficiency and Tissue-Specific Targeting as Key Differentiators
While GalNAc conjugates have solved liver-specific delivery for siRNA and ASO (enabling subcutaneous administration, convenient for chronic diseases), delivery to other tissues (muscle, CNS, lung, kidney, tumors) remains a challenge. Several approaches are in clinical development: (1) LNPs with targeting ligands (e.g., anti-TfR antibodies for brain delivery, integrin-targeting peptides for tumors); (2) exosome-based delivery (endogenous vesicles modified to carry nucleic acids); (3) polymer-based nanoparticles (PEI, PLGA); (4) viral vectors (AAV for gene editing, though different regulatory path). Alnylam’s C16 conjugation for CNS delivery (animal models) and Ionis’ LICA (ligand-conjugated antisense) platform are notable advances. Companies with tissue-specific delivery solutions will capture significant value in the value chain.
Industry Layering Perspective: Type Comparison (ASO vs. siRNA vs. mRNA)
- ASO (Antisense) – Single-stranded, chemically modified (phosphorothioate backbone, 2′-O-methoxyethyl, 2′-fluoro). Delivery: naked or with GalNAc (liver). Targets: nuclear and cytoplasmic RNA. Mechanism: splice modulation, RNase H-mediated degradation. Advantages: wide tissue distribution (including CNS), mature manufacturing (solid-phase synthesis). Disadvantages: potential for toxicity (pro-inflammatory, complement activation). Market status: established (multiple approved drugs), steady growth (6-8% CAGR).
- siRNA (RNA interference) – Double-stranded, chemically modified (2′-OMe, 2′-F, phosphorothioate). Delivery: GalNAc (liver) or LNP. Targets: cytoplasmic mRNA only. Mechanism: RISC-mediated mRNA degradation. Advantages: high potency, durable effect (months per dose), favorable safety profile after GalNAc conjugation. Disadvantages: liver-limited without advanced delivery. Market status: emerging (several approved, blockbuster potential in hypercholesterolemia), fastest-growing segment (10-12% CAGR).
- mRNA – Single-stranded, modified nucleotides (pseudouridine, N1-methylpseudouridine) to reduce immunogenicity. Delivery: LNP essential. Targets: cytoplasmic (translation machinery). Mechanism: protein expression (transient). Advantages: rapid development (weeks from sequence to candidate), scalable manufacturing (enzymatic transcription), platformizable (same LNP-mRNA platform for multiple antigens). Disadvantages: cold chain requirements (-20°C to -80°C), potential immunogenicity (innate and adaptive responses). Market status: mature for vaccines, emerging for protein replacement and cancer immunotherapy (10-12% CAGR from COVID-19 baseline).
3. Market Segmentation and Competitive Landscape
Segment by Technology Type (QYResearch Classification):
- Antisense Oligonucleotides (ASO) – Established segment (~30-35% of market revenue). Key players: Ionis Pharmaceuticals (Spinraza, Tegsedi, numerous pipeline), Sarepta Therapeutics (Exondys 51, Amondys 45, Vyondys 53 for Duchenne), Biogen (partner for Spinraza). Growth driven by expansion into new indications (cardiovascular, neurological, rare diseases).
- siRNA – Fastest-growing segment (~25-30% of market revenue). Key players: Alnylam (Onpattro, Givlaari, Oxlumo, Leqvio partnership with Novartis). Additional players: Dicerna (acquired by Novo Nordisk), Silence Therapeutics. Growth driven by chronic disease applications (hypercholesterolemia, complement-mediated diseases, hypertension).
- mRNA – Significant segment (~25-30% of market revenue). Key players: Moderna Therapeutics (Spikevax, pipeline: RSV, CMV, cancer), Pfizer/BioNTech (Comirnaty, pipeline: influenza, shingles), CureVac, Translate Bio (Sanofi). Growth driven by endemic vaccine demand, variant updates, and pipeline expansion.
- Other (aptamers, gene editing vectors) – Smaller segment (~5-10% of market revenue). Gene editing (CRISPR) companies: CRISPR Therapeutics (exa-cel for sickle cell disease, approved in UK 2023, FDA decision 2024?), Editas Medicine, Intellia Therapeutics.
Segment by Application (Therapeutic Area):
- Neuromuscular Diseases – Largest segment (~25-30% of revenue). Includes SMA, DMD, ALS, myotonic dystrophy. High-value, orphan disease pricing (Spinraza USD 125,000 per vial × 3-4 loading doses then quarterly).
- hATTR – Significant segment (~10-15% of revenue). Hereditary transthyretin amyloidosis. Alnylam’s Onpattro (IV) and Ionis’ Tegsedi (subcutaneous) compete with Pfizer’s Vyndaqel (small molecule TTR stabilizer).
- COVID-19 – Variable segment (declining from peak 2021-2022, but endemic demand stabilizes). mRNA vaccines now annual booster market similar to influenza.
- Other – Hypercholesterolemia (inclisiran), acute hepatic porphyria, primary hyperoxaluria, oncology (mRNA cancer vaccines, siRNA targeting KRAS, MYC), and expanding pipeline.
Key Market Players (QYResearch-identified):
The market is concentrated among platform leaders and large pharma partners:
ASO Leaders: Sarepta Therapeutics (US) – Duchenne muscular dystrophy franchise. Ionis Pharmaceuticals (US) – Broad ASO pipeline, partnerships with Biogen, Roche, Novartis, AstraZeneca. Biogen (US) – Partner for Spinraza. Nippon Shinyaku (Japan) – Viltepso for DMD.
siRNA Leaders: Alnylam (US) – The dominant siRNA player, four approved drugs, deep pipeline (includes hypertension, complement-mediated diseases). Novartis (Switzerland) – Leqvio (inclisiran) commercial partner, also pipeline. Novo Nordisk (Denmark) – Acquired Dicerna, expanding siRNA for cardiometabolic diseases. AstraZeneca (UK/Sweden) – Partnership with Ionis for eplontersen (hATTR, Phase III).
mRNA Leaders: Moderna Therapeutics (US) – Spikevax (COVID-19), pipeline includes RSV (positive Phase III), CMV (Phase III), personalized cancer vaccine (mRNA-4157 with Merck). Pfizer (US) – Comirnaty (partner with BioNTech), also internal mRNA programs. BioNTech (Germany) – Comirnaty (Pfizer partner), pipeline includes cancer vaccines, shingles, malaria. Jazz Pharmaceuticals (Ireland) – Acquired? (Jazz is not primarily nucleic acid). Astellas Pharma (Japan) – Gene therapy and nucleic acid programs.
Other Key Players: Novo Nordisk (above), AstraZeneca (above), Sobi (Sweden – rare disease focus, not primarily nucleic acid but partner). The market is moderately concentrated at the technology platform level (Alnylam in siRNA, Ionis in ASO, Moderna/BioNTech in mRNA) but with multiple large pharma partners and licensees.
4. Exclusive Expert Insights and Recent Developments (Q4 2025 – Q2 2026)
Insight #1 – Downstream Demand Expanding from Rare Diseases to Chronic Conditions
Downstream demand is expanding from research and early clinical use to broader therapeutic and prophylactic applications. Clinically, rare diseases (SMA, DMD, hATTR), genetic/metabolic disorders (hypercholesterolemia, porphyria), oncology (mRNA cancer vaccines, siRNA targeting oncogenes), and infectious disease vaccines (COVID-19, influenza, RSV) drive strong demand for nucleic acid therapeutics. Market-wise, healthcare institutions, specialty treatment centers (rare disease centers, comprehensive cancer centers), and commercial distribution networks are scaling to support chronic administration (inclisiran twice-yearly subcutaneous injection, requiring patient enrollment and compliance programs) and cold-chain logistics (mRNA vaccines require -20°C to -80°C storage). Payer and buyer behavior is shifting from pilot or grant-driven uptake to value-driven procurement, with an increased focus on real-world effectiveness, cost-effectiveness, and accessibility—factors that will amplify demand for standardized, scalable nucleic acid formulations.
Insight #2 – Upstream Supply Concentration and Geopolitical Risks
Key upstream inputs for nucleic acid drugs include synthesized and modified nucleotides (phosphoramidites, pseudouridine triphosphate, N1-methylpseudouridine triphosphate), carrier materials (LNP components: ionizable lipids, phospholipids, cholesterol, PEG-lipids), high-purity enzymes and reagents (T7 RNA polymerase, DNase, RNase inhibitor, capping enzymes), and GMP-grade consumables and equipment (synthesizers, chromatographs, fill-finish lines). As mRNA and siRNA products move to large-scale production (hundreds of kilograms annually for blockbuster products), upstream requirements for quality, traceability, and batch consistency intensify, driving higher supplier concentration and the need for long-term supply agreements. Geographic dependencies (key lipid manufacturers in Europe and US; modified nucleotide suppliers in US, Europe, Asia) and geopolitical risks (US-China trade tensions, export controls on biomanufacturing equipment) are incentivizing companies to pursue localization and strategic inventory to ensure supply continuity and manufacturing resilience. For example, Moderna has established mRNA manufacturing in Australia, Canada, Kenya, and South Korea, with local supply agreements for raw materials.
Insight #3 – Pricing and Reimbursement: Value-Based Models Emerge
Nucleic acid drugs are among the most expensive therapeutics (Spinraza USD 750,000 first-year, USD 375,000 annually thereafter; Onpattro USD 450,000 annually; Zolgensma gene therapy USD 2.1 million one-time). Payers (CMS, NHS, statutory health insurers in Germany, etc.) are demanding outcomes-based agreements (OBAs) where reimbursement is linked to clinical response. For inclisiran (hypercholesterolemia), Novartis agreed to a “pay-for-performance” model with multiple US commercial payers: if LDL-cholesterol reduction targets are not met, Novartis refunds part of the drug cost. For mRNA vaccines, volume-based pricing (USD 30-50 per dose) is more affordable but still requires government procurement. For companies developing nucleic acid drugs, early engagement with payers (HTA agencies, insurance medical directors) and demonstration of long-term cost-effectiveness (reduced hospitalizations, avoided surgeries, improved quality of life) are critical for market access.
Typical User Case (Q1 2026 – US Integrated Healthcare System, Payer Perspective):
A large US integrated healthcare system (Kaiser Permanente scale, but hypothetical) evaluated its coverage policy for inclisiran (siRNA for hypercholesterolemia) versus PCSK9 monoclonal antibodies (evolocumab, alirocumab) and statins. Clinical data: inclisiran (twice-yearly subcutaneous) achieved similar LDL-cholesterol reduction (50-60%) to PCSK9 mAbs (every 2-4 weeks injections). At annual drug cost (USD 6,500 vs. mAbs USD 14,000), inclisiran was cost-saving. The healthcare system added inclisiran to its formulary with prior authorization for: (1) patients with ASCVD or heterozygous familial hypercholesterolemia (HeFH) on maximally tolerated statin with LDL >70 mg/dL; (2) statin-intolerant patients with similar criteria. The system negotiated a confidential discount with Novartis (including an outcomes-based component). Within 6 months, 2,500 patients were initiated on inclisiran, projected to reduce annual drug spend by USD 18.75 million compared to mAbs, with anticipated reductions in cardiovascular events (MI, stroke) modeled over 5 years.
5. Technical Challenges and Future Pathways
Despite promising prospects, commercialization faces material risks:
- Delivery efficiency and tissue-specific targeting – While GalNAc (liver) solved hepatic delivery, extra-hepatic delivery (CNS, muscle, lung, kidney, tumors) remains a significant challenge. LNPs with targeting ligands are in early clinical trials, but off-target effects and immunogenicity are concerns. Without delivery solutions, nucleic acid drugs will be limited to liver and locally accessible diseases.
- Long-term safety – Chronic administration of nucleic acid drugs (e.g., inclisiran lifelong twice-yearly, Spinraza lifelong quarterly) requires extensive long-term safety data. Theoretical risks include: (1) off-target RNAi activity (siRNA) or hybridization (ASO), (2) accumulation of delivery vehicle components (LNPs persist in tissues), (3) immune responses (anti-PEG antibodies reducing efficacy), (4) rare but serious adverse events (Spinraza has boxed warning for thrombocytopenia, Tegsedi for glomerulonephritis). Regulatory agencies require long-term follow-up (5-10 years) in patient registries.
- Regulatory heterogeneity and reimbursement uncertainty – Regulatory approval pathways differ: FDA requires dedicated IND and NDA/BLA; EMA centralized procedure; China NMPA separate requirements. For gene editing products (CRISPR), additional biosafety review is required. Reimbursement uncertainty (value-based pricing, discounts, rebates) can slow adoption, particularly in fragmented healthcare systems (e.g., US multiple commercial payers, each with own formulary decisions). For companies, parallel global regulatory strategy and early HTA engagement are essential.
Future Direction: The nucleic acid-based drugs market will continue its 7-8% CAGR through 2031, driven by: (1) platform expansion beyond rare diseases into chronic conditions (cardiovascular, metabolic), (2) delivery technology breakthroughs enabling extra-hepatic targeting, (3) regulatory acceptance of platform technologies (reducing per-product development time), (4) local manufacturing capacity build-out for supply chain resilience, (5) value-based pricing and outcomes agreements facilitating payer acceptance. Key strategic imperatives for companies: (1) invest in differentiated delivery platforms (tissue targeting beyond liver), (2) develop scalable, cost-effective manufacturing (reducing cost of goods), (3) pursue strategic partnerships with large pharma for commercialization and distribution, (4) generate real-world evidence for long-term safety and cost-effectiveness. For investors, the nucleic acid therapeutics sector remains a high-growth, high-conviction area of biopharma, with the highest returns likely accruing to platform companies with validated delivery technology and diverse pipelines.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
